Owned and operated by Baba Kahn, a CF veteran 
Independent analytical report
Retatrutide 20 mg — Task 203802
Review the report details, original PDF and Janoshik verification record.
Report summary
- Compound
- Retatrutide
- Strength
- 20 mg
- Reported purity
- 99.311%
- Tested quantity
- 18.08 mg
- Report date
- July 25, 2026
- Janoshik task ID
- #203802
Analysis completed 25 July 2026 on a 20 mg Retatrutide presentation. Janoshik measured 18.08 mg of Retatrutide at 99.311 percent purity.
As with the other GLP-1 submissions in this run, the laboratory ran a blind panel across Semaglutide, Tirzepatide and Retatrutide. Readers comparing this against the January 2026 analysis of the same presentation will see the two figures differ; both certificates are published in full and each describes only the vial submitted to the laboratory on that occasion.
This certificate describes the submitted sample identified in the report. It does not establish clinical safety, efficacy, suitability for human or veterinary use, or the specifications of future inventory.
